Tissue Regenix Group PLC Director/PDMR Shareholding (1486Y)

TIDMTRX

RNS Number : 1486Y

Tissue Regenix Group PLC

11 May 2021

Tissue Regenix Group plc

("Tissue Regenix" or "the Group")

Director/PDMR Shareholding

Tissue Regenix (AIM: TRX), the regenerative medical devices company, announces that on 10 May 2021, Daniel Lee, Chief Executive Officer, acquired 2,068,750 Ordinary Shares in the Group at a price of 0.69 pence per share for a total consideration of GBP14,274.38.

As a result, Daniel Lee's beneficial interest in the Company is 2,068,750 Ordinary Shares, representing 0.03% of the total issued share capital.

For more information:

 
 Tissue Regenix Group plc                                    www.tissueregenix.com 
  David Cocke, Chief Financial Officer                             Via Walbrook PR 
 
 Stifel Nicolaus Europe Limited (Nominated Adviser         Tel: [phone] 
  and Broker) 
  Ben Maddison / Alex Price 
 Walbrook PR Ltd                                          Tel: [phone] 
  Alice Woodings / Paul McManus                       [e-mail] 
 
 

About Tissue Regenix ( www.tissueregenix.com )

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL(R)') technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or worn-out body parts. Current applications address many critical clinical needs such as sports medicine, heart valve replacement and wound care.

In August 2017 Tissue Regenix acquired CellRight Technologies(R), a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and soft tissue scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight's human osteobiologics may be used in spine, trauma, general orthopaedic, foot & ankle, dental, and sports medicine surgical procedures.

The information contained in this notification is disclosed in accordance with the requirements of the EU Market Abuse Regulation as it forms part of UK law by virtue of the European Union (Withdrawal) Act 2018. The notification form is set out below.

 
   1   Details of the person discharging managerial responsibilities 
        / person closely associated 
 a)    Name                      Daniel Lee 
      ------------------------  -------------------------------------- 
 2     Reason for the notification 
      ---------------------------------------------------------------- 
 a)    Position/status           Chief Executive Officer 
      ------------------------  -------------------------------------- 
 b)    Initial notification      Initial notification 
        /Amendment 
      ------------------------  -------------------------------------- 
 3     Details of the issuer, emission allowance market participant, 
        auction platform, auctioneer or auction monitor 
      ---------------------------------------------------------------- 
 a)    Name                      Tissue Regenix Group plc 
      ------------------------  -------------------------------------- 
 b)    LEI                         213800PNOD5UHQUFJI36 
      ------------------------  -------------------------------------- 
 4     Details of the transaction(s): section to be repeated 
        for (i) each type of instrument; (ii) each type of 
        transaction; (iii) each date; and (iv) each place where 
        transactions have been conducted 
      ---------------------------------------------------------------- 
 a)    Description                Ordinary Shares of 0.1p each 
        of the financial 
        instrument, 
        type of instrument 
      ------------------------  -------------------------------------- 
 b)    Identification            GB00B5SGVL29 
        code 
      ------------------------  -------------------------------------- 
 c)    Nature of the             Acquisition of Ordinary Shares 
        transaction 
      ------------------------  -------------------------------------- 
 d)    Price(s) and                Price   Volume 
        volume(s)                   0.69p   2,068,750 
                                           ---------- 
      ------------------------  -------------------------------------- 
 d)    Aggregated                 2,068,750 
        information                GBP14,274.38 
        - Aggregated 
        volume 
        - Price 
      ------------------------  -------------------------------------- 
 e)    Date of the               10 May 2021 
        transaction 
      ------------------------  -------------------------------------- 
 f)    Place of the              London Stock Exchange, AIM Market 
        transaction 
      ------------------------  -------------------------------------- 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHBCGDUCSBDGBG

(END) Dow Jones Newswires

May 11, 2021 02:00 ET (06:00 GMT)